Zions Bancorporation N.A. Purchases 1,984 Shares of Stryker Co. (NYSE:SYK)

Zions Bancorporation N.A. boosted its position in Stryker Co. (NYSE:SYK - Free Report) by 17.1% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 13,619 shares of the medical technology company's stock after acquiring an additional 1,984 shares during the quarter. Zions Bancorporation N.A.'s holdings in Stryker were worth $4,920,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in the company. Patrick M Sweeney & Associates Inc. increased its stake in Stryker by 1.5% in the third quarter. Patrick M Sweeney & Associates Inc. now owns 2,194 shares of the medical technology company's stock valued at $793,000 after acquiring an additional 32 shares during the last quarter. Versant Capital Management Inc grew its stake in shares of Stryker by 4.0% during the second quarter. Versant Capital Management Inc now owns 864 shares of the medical technology company's stock worth $294,000 after buying an additional 33 shares during the last quarter. Stanley Laman Group Ltd. grew its stake in shares of Stryker by 4.6% during the second quarter. Stanley Laman Group Ltd. now owns 752 shares of the medical technology company's stock worth $256,000 after buying an additional 33 shares during the last quarter. Plimoth Trust Co. LLC grew its stake in shares of Stryker by 0.3% during the second quarter. Plimoth Trust Co. LLC now owns 9,476 shares of the medical technology company's stock worth $3,224,000 after buying an additional 33 shares during the last quarter. Finally, Grimes & Company Inc. grew its stake in shares of Stryker by 0.4% during the third quarter. Grimes & Company Inc. now owns 8,239 shares of the medical technology company's stock worth $2,977,000 after buying an additional 33 shares during the last quarter. 77.09% of the stock is owned by institutional investors.

Insider Buying and Selling at Stryker

In other news, insider Viju Menon sold 600 shares of the business's stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $355.00, for a total transaction of $213,000.00. Following the completion of the sale, the insider now directly owns 9,069 shares of the company's stock, valued at $3,219,495. The trade was a 6.21 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other Stryker news, CEO Kevin Lobo sold 57,313 shares of the company's stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $368.70, for a total value of $21,131,303.10. Following the completion of the sale, the chief executive officer now directly owns 100,027 shares of the company's stock, valued at approximately $36,879,954.90. This represents a 36.43 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Viju Menon sold 600 shares of the company's stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $355.00, for a total transaction of $213,000.00. Following the completion of the sale, the insider now directly owns 9,069 shares of the company's stock, valued at $3,219,495. The trade was a 6.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 67,381 shares of company stock valued at $24,825,275. Corporate insiders own 5.90% of the company's stock.

Stryker Stock Down 1.3 %

SYK traded down $5.06 during midday trading on Thursday, hitting $383.28. The company had a trading volume of 1,762,772 shares, compared to its average volume of 1,259,190. Stryker Co. has a 52 week low of $282.35 and a 52 week high of $392.70. The company has a quick ratio of 1.22, a current ratio of 1.91 and a debt-to-equity ratio of 0.66. The company has a market capitalization of $146.11 billion, a price-to-earnings ratio of 41.62, a PEG ratio of 2.92 and a beta of 0.91. The stock's 50 day moving average price is $362.94 and its 200 day moving average price is $346.72.

Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings results on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share for the quarter, beating the consensus estimate of $2.77 by $0.10. Stryker had a net margin of 16.34% and a return on equity of 23.07%. The firm had revenue of $5.49 billion during the quarter, compared to the consensus estimate of $5.37 billion. During the same period in the previous year, the firm posted $2.46 earnings per share. The business's revenue was up 11.9% compared to the same quarter last year. On average, research analysts anticipate that Stryker Co. will post 12.06 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

SYK has been the topic of a number of research reports. Evercore ISI boosted their target price on shares of Stryker from $380.00 to $384.00 and gave the stock an "outperform" rating in a research note on Wednesday, October 30th. Citigroup boosted their target price on shares of Stryker from $406.00 to $411.00 and gave the stock a "buy" rating in a research note on Thursday, October 31st. JPMorgan Chase & Co. boosted their target price on shares of Stryker from $375.00 to $420.00 and gave the stock an "overweight" rating in a research note on Wednesday, October 30th. Piper Sandler reiterated an "overweight" rating and set a $420.00 price target (up previously from $380.00) on shares of Stryker in a report on Wednesday, October 30th. Finally, BTIG Research lifted their price target on shares of Stryker from $383.00 to $394.00 and gave the stock a "buy" rating in a report on Wednesday, October 30th. Four research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $393.65.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.